TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Satisfactory completion of KKP's sponsored KRN23-INT-001 clinical trial~2. eGFR ≥ 60 mL/min~3. Corrected Ca \< 10.8 mg/dL~4. For female of child-bearing potential, a negative serum pregnancy test~5. A willingness to utilize adequate contraception and not become pregnant \[or to have their partner(s) become pregnant\] during the study~6. Additional inclusion criteria apply~Exclusion Criteria:~1. Subject experienced a safety-related event in the KRN23-INT-001 study~2. Pregnant or lactating female subject or pregnant or female planning to become pregnant during the study~3. Receipt of a live (attenuated) vaccine (except for influenza vaccines) during the course of the KRN23-INT-001 study and/or of this study~4. Condition which could present a concern for either the subject's safety or difficulty with data interpretation~5. Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21-60 years old~* Smoke \>5 cigarettes per day~* \>1 year of daily smoking~* No quit attempt in prior month and not planning to quit smoking within next 3 months~* Able to understand and consent to study procedures~* High school or lower educational attainment or annual household income \< $50,000~* Plan to live in local area next 3 months~* Women not pregnant or nursing and taking steps to avoid pregnancy~* Able to read and write in English~* Access to computer with internet service that allows for Zoom~Exclusion Criteria:~* Use of non-cigarette tobacco products in the past 7 days~* Use of illicit substances more than once a week in the past 3 months (excluding marijuana)~* Current alcohol abuse impairing participation~* MRI safety contraindications (e.g., metal implants, claustrophobia)~* Unstable or significant medical conditions (e.g., chronic obstructive pulmonary disorder, coronary heart disease)~* Major neurological conditions or brain trauma~* Major surgeries planned in next 3 months~* Use of smoking cessation medication in prior month (e.g., varenicline, patch)~* Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months~* Unwillingness to provide urine samples~* Unwilling to smoke study assigned cigarettes for the remainder of the trial~* Plans to move or take extended travel out of the area in the next 3 months~* Any other condition or situation that would, in the investigator's opinion, make it unlikely that the participant could comply with the study protocol~* Self-reported color blindness~* Left-handedness~* Smell dysfunction as determined via standardized assessment

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Very low nicotine content cigarettes (Type: EXPERIMENTAL): Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
- Normal nicotine content cigarettes (Type: PLACEBO_COMPARATOR): Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* intact maxillary dental arch suitable to retain a palatal appliance, an intact mandibular dental arch and a stimulated/unstimulated saliva flow rate of ≥ 0.8 milliliter/minute (ml/min) and ≥ 0.2 ml/min respectively.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Low ppm fluoride dentifrice (Type: EXPERIMENTAL): Low ppm fluoride as sodium fluoride in a silica base dentifrice
- Medium ppm fluoride dentifrice (Type: EXPERIMENTAL): Medium ppm fluoride as sodium fluoride in a silica base dentifrice
- High ppm fluoride dentifrice (Type: EXPERIMENTAL): High ppm fluoride as sodium fluoride in a silica base dentifrice
- No fluoride dentifrice (Type: PLACEBO_COMPARATOR): no added fluoride in a silica base dentifrice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Established clinical diagnosis of type 2 diabetes. Treatment with a stable metformin monotherapy, for at least 8 weeks prior to Visit 1~* HbA1c ≥7.0% and ≤9.0%~Exclusion Criteria:~* Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma. Current use of any injectable or oral antihyperglycemic agent excluding metformin.~* Renal impairment as defined by a creatinine clearance \<60 mL/min~* Individuals who, in the opinion of the investigator, in which participation in this study may pose a significant risk to the patient and could render the patient unable to successfully complete the study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Saxagliptin 5 mg
- 2 (Type: ACTIVE_COMPARATOR): Glimepiride 1 - 6 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-~Patients must have:~Major depressive disorder that is responsive to acute phase ECT.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients must be \> 12 months and \< 21 years of age at the time of study entry.~* Weight: Patient must be more than or equal to 10 Kilograms.~Histological Diagnosis:~* Patients must have had histological verification of the malignancy at some time prior to study entry.~* All solid tumors are eligible with the exclusion of lymphomas. For patients with neuroblastoma, diagnosis based on elevated catecholamines in the urine and tumor cells on bone marrow aspirates/biopsies is acceptable.~* For patients with germ cell tumors, diagnosis based on elevated tumor markers (serum alpha fetoprotein and/or serum beta human chorionic gonadotropin) and radiographic evidence of disease is acceptable.~Disease Status:~* Disease must have failed standard therapy (therapies) or be a disease for which no standard therapy exists.~* Patient with stable disease on other therapies are not eligible.~Performance Level:~* Karnofsky \> 50% for patients \>16 years of age and Lansky \> 50 for children \< 16 years of age (Appendix I).~* Life Expectancy: Must be \> 8 weeks.~Exclusion Criteria:~* Patients who have received bevacizumab and/or Irinotecan previously are ineligible. Non brain tumor patients who have previously received Temozolomide are ineligible.~* Pregnancy or Breast-Feeding: Pregnant patients are ineligible for this study due to the known teratogenic effects of the cytotoxic agents. Pregnancy tests must be obtained in females of childbearing potential prior to enrollment.~* Lactating women must agree not to breast-feed.~* Males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method.~* Patients Who Have an Uncontrolled Infection will not be eligible for enrollment until all infections are under control.~* Clinically Significant Unrelated Systemic Illness: Patients with serious infections or significant pulmonary, hepatic, renal, or other end-organ dysfunction which in the judgment of the Principal or Co-Investigators would compromise the patient's ability to tolerate prescribed chemotherapy or are likely to interfere with the study procedures or results will not be eligible.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Key Inclusion Criteria:~* Individuals with chronic HCV infection~* HCV RNA ≥10\^4 IU/mL at screening~* HCV genotype 1~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female~* Current or prior history of hepatic decompensation~* Hepatocellular carcinoma (HCC) or other clinically significant malignancy~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VOX+SOF/VEL 6 wk, TN, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
- VOX+SOF/VEL 8 wk, TN, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
- VOX+SOF/VEL 6 wk, TN, with cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk, TN, with cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
- VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
- VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
- VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
- VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis (Type: EXPERIMENTAL): GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
- VOX+SOF/VEL 12 wk (GS-US-338-1121) (Type: EXPERIMENTAL): VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Octreotide Treatment of Acromegaly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GH nadir during a standard 75 g OGTT \>= 5.0 mmol/L.~* Pituitary tumor by MRI-scan.~Exclusion Criteria:~* Immediate surgery indicated by usual clinical criteria.~* Pregnant.~* Known adverse effects of octreotide.~* Unfit for participation by any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- octreotide (Type: EXPERIMENTAL): 6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
- standard surgery (Type: ACTIVE_COMPARATOR): Standard transphenoidal surgery soon after the diagnosis of acromegaly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years of age or older~* Admitted for respiratory failure primarily due to COPD exacerbation~* Requiring non-invasive ventilation~* Respiratory distress, as evidenced by moderate-to-severe dyspnea and use of accessory muscles of respiration~* Hypercapnic respiratory failure~* High respiratory rate~Exclusion Criteria:~* Respiratory arrest or the need for immediate intubation~* Upper airways obstruction~* Facial trauma~* Inability to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HMW-HA (Type: EXPERIMENTAL): HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
- Placebo (Type: PLACEBO_COMPARATOR): 5 ml of saline via nebulizer b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and non-pregnant, non breast-feeding female outpatients at least 18 years of age (no upper age limit).~2. History of constipation; the subject reports, ona average,two of fewer spontaneous bowel movements per week that result in a feeling of complete evacuation and one or more of the following for at least 6 months before the selection visit:~   1. very hard (little balls) and/or hard stools at least a quarter of the stools~  2. sensation of incomplete evacuation following at least a quarter of the stools~  3. straining at defecation at least a quarter of the time. The above criteria are only applicable for spontaneous bowel movements, i.e., not preceded within a period of 24 hours by the intake of a laxative agent or by the use of an enema.~Subjects who never have spontaneous bowel movements are considered to be constipated and are eligible for the trial.~Exclusion Criteria:~1. Subjects in whom constipation is thought to be drug-induced, or subjects using any disallowed medication.~2. Subjects suffering from endocrine disorders, metabolic disorders or neurologic disorders.~3. Subjects with a megacolon/megarectum or a diagnosis of pseudo-obstruction.~4. Constipation as a result of surgery.~5. Known or suspected organic disorders of the large bowel, i.e. obstruction, carcinoma, or inflammatory bowel disease.~6. Subjects with severe and clinically uncontrolled cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including active alcohol or drug abuse), cancer or AIDS, and other gastrointestinal or endocrine disorders.~7. Subjects with impaired renal function.~8. Subjects with clinically significant abnormalities of haematology, urinalysis, or blood chemistry.~9. Females of child-bearing potential without adequate contraceptive protection during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Prucalopride 2 mg
- 3 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: ACTIVE_COMPARATOR): Prucalopride 4 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~-Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 (NCT00420212) or 109MS302 (NCT00451451).~Key Exclusion Criteria:~* Any significant change in medical history from 109MS301 or 109MS302 that would have excluded subject's participation from their previous study.~* Subjects from 109MS301 or 109MS302 who discontinued oral study treatment due to an AE or due to reasons other than protocol-defined relapse/disability progression.~* Subjects from 109MS301 or 109MS302 who discontinued study treatment due to disability progression or relapses and did not follow the modified visit schedule up to Week 96.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 58 Years
- Healthy Volunteers: f

Study Arms:
- BG00012 plus placebo (Type: EXPERIMENTAL): In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
- BG00012 (Type: EXPERIMENTAL): In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants of both genders who are 18 years or older~* Diagnosis of RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) of 1987 for the RA classification~* Participants with medically prescribed or being administered with unique rituximab infusion in the least 3 days, according to the approved label~* Ability to meet the program's requirements and to voluntarily sign the Informed Consent Term.~Exclusion Criteria:~* Participants who have received any investigational medication within less than or equal to (\<=) 1 year before the first dose of the currently indicated treatment~* Participants with an active infection~* Participants with conditions that may interfere in the ability to understand the requests of data collection and to obey to the study's requirements~* Functional Class IV defined based on the ACR functionality criteria for RA~* Participants who can not or who do not want, for any reason, to answer the questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete